Intellia Therapeutics Stock News

Equities research analysts predict that Intellia Therapeutics, Inc. (NASDAQ:NTLA) will post sales of $10.31 million for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for Intellia Therapeutics earnings, with estimates ranging from $4.67 million to $28.98 million. Intellia Therapeutics posted sales of $6.60 million in the same quarter last year, which would []

Equities analysts expect Intellia Therapeutics, Inc. (NASDAQ:NTLA) to report earnings per share (EPS) of ($0.89) for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Intellia Therapeutics earnings, with the lowest EPS estimate coming in at ($1.12) and the highest estimate coming in at ($0.64). Intellia Therapeutics reported earnings per share of []

Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Q3 earnings are out: Intellia has a strong cash position. NTLA-2001 shows good results in dose escalation and no safety concerns.

Brokerages expect that Intellia Therapeutics, Inc. (NASDAQ:NTLA) will announce earnings of ($0.89) per share for the current quarter, Zacks reports. Eight analysts have made estimates for Intellia Therapeutics earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($1.12). Intellia Therapeutics reported earnings of ($0.69) per share in []

Related Stocks: SHOP , SEDG , PFE , GE , GS , UPST , EA , DOCS , KVSB , CZR , Z , SBUX , NTLA , JPM ,

Related Stocks: EPZM , MRUS , ADCT , YMAB , MEIP , NTLA , BCRX , CYTK , VSTM , GERN ,

Related Stocks: ^BFX , BCRX , NTLA , EPZM , EPIX , NEO , MEIP ,

Intellia Therapeutics, Inc. (NTLA) CEO Dr. John Leonard on Q3 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/

Investing gets simple if you have to put all of your eggs in one basket.

Intellia Therapeutics Inc. ( NTLA , Financial) is following in the footsteps of several members of Big Pharma that have hooked up with smaller, specialized biotechs to develop gene therapies to treat

For those not familiar with the Russell 2000 ( ^RUT , Financial), it is an index of small-cap stocks which includes the likes of AMC Entertainment Holidngs ( AMC , Financial), Intellia Therapeutics (

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.